Garfield Alastair 4

What Happened

• Alastair Garfield, Chief Scientific Officer of Rhythm Pharmaceuticals (RYTM), received awards totaling 41,650 restricted stock units (16,650 + 25,000) on February 11, 2026. The grants were recorded at $0.00 (i.e., awards/derivatives) and represent contingent rights to common shares rather than open‑market purchases or sales. These are compensation/retention awards and do not reflect an immediate purchase or sale of shares.

Key Details

• Transaction date: February 11, 2026; Filing date (Form 4): February 13, 2026 — appears timely (within the usual 2‑business‑day window).
• Grant price: $0.00 (awarded RSUs/derivative).
• Total RSUs granted: 41,650 (16,650 + 25,000).
• Shares owned after transaction: not disclosed in the provided filing details.
• Footnotes of note:
  • F1: Each RSU converts to one common share upon vesting.
  • F2: RSUs vest 25% on each of Feb 1 in 2027, 2028, 2029 and 2030; no expiration date.
  • F3: The filing also references stock options granted Feb 11, 2026 that vest in 16 equal installments every three months of continued service (details/amounts not specified here).

Context

• These were awards (A), not purchases (P) or sales (S). RSUs are contingent on continued service and vest over time, so they are standard executive compensation rather than a direct market bet. They do not indicate an immediate change in share ownership until vested and issued.